EP0822983A4 - Apopaine - Google Patents

Apopaine

Info

Publication number
EP0822983A4
EP0822983A4 EP96913801A EP96913801A EP0822983A4 EP 0822983 A4 EP0822983 A4 EP 0822983A4 EP 96913801 A EP96913801 A EP 96913801A EP 96913801 A EP96913801 A EP 96913801A EP 0822983 A4 EP0822983 A4 EP 0822983A4
Authority
EP
European Patent Office
Prior art keywords
apopain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96913801A
Other languages
German (de)
English (en)
Other versions
EP0822983A1 (fr
Inventor
Douglas K Miller
Nancy A Thornberry
Donald W Nicholson
Ambereen Ali
John P Vaillancourt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Publication of EP0822983A1 publication Critical patent/EP0822983A1/fr
Publication of EP0822983A4 publication Critical patent/EP0822983A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP96913801A 1995-04-21 1996-04-17 Apopaine Withdrawn EP0822983A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42655795A 1995-04-21 1995-04-21
US426557 1995-04-21
PCT/US1996/005282 WO1996033268A1 (fr) 1995-04-21 1996-04-17 Apopaïne

Publications (2)

Publication Number Publication Date
EP0822983A1 EP0822983A1 (fr) 1998-02-11
EP0822983A4 true EP0822983A4 (fr) 2004-12-15

Family

ID=23691273

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96913801A Withdrawn EP0822983A4 (fr) 1995-04-21 1996-04-17 Apopaine

Country Status (4)

Country Link
EP (1) EP0822983A4 (fr)
JP (1) JPH11504209A (fr)
CA (1) CA2218679A1 (fr)
WO (1) WO1996033268A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538121B1 (en) * 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US6835555B1 (en) 1994-11-01 2004-12-28 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
WO1997031018A1 (fr) * 1996-02-23 1997-08-28 Merck & Co., Inc. Structure cristalline d'apopaine et son utilisation
US6180402B1 (en) * 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
GB2324529A (en) * 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
DE19820328A1 (de) * 1998-05-07 1999-11-11 Roche Diagnostics Gmbh Verfahren und Reagenz zum Nachweis apoptotischer Zellen bzw. einer bei Apoptose aktivierten Protease
JP2002515490A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
DE10006889A1 (de) * 2000-02-16 2001-09-06 Procorde Gmbh Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen
AU2001295778A1 (en) * 2000-10-20 2002-04-29 Inpharmatica Limited Novel cysteine proteases and uses thereof
CN116731101A (zh) 2016-06-01 2023-09-12 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013603A1 (fr) * 1994-11-01 1996-05-09 Human Genome Sciences, Inc. PROTEASE-3 ET 4 D'APOPTOSE DE TYPE ENZYME DE CONVERSION D'INTERLEUKINE-1 $g(b)
WO1996025501A2 (fr) * 1995-02-13 1996-08-22 The Regents Of The University Of Michigan Composition et procede de regulation de l'apoptose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013603A1 (fr) * 1994-11-01 1996-05-09 Human Genome Sciences, Inc. PROTEASE-3 ET 4 D'APOPTOSE DE TYPE ENZYME DE CONVERSION D'INTERLEUKINE-1 $g(b)
WO1996025501A2 (fr) * 1995-02-13 1996-08-22 The Regents Of The University Of Michigan Composition et procede de regulation de l'apoptose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FERNANDES-ALNEMRI T ET AL: "MCH3, A NOVEL HUMAN APOPTOTIC CYSTEINE PROTEASE HIGHLY RELATED TO CPP32", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 24, 15 December 1995 (1995-12-15), pages 6045 - 6052, XP000614740, ISSN: 0008-5472 *
KAUFMANN S H ET AL: "SPECIFIC PROTEOLYTIC CLEAVAGE OF POLY(ADP-RIBOSE) POLYMERASE: AN EARLY MARKER OF CHEMOTHERAPY-INDUCED APOPTOSIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, no. 17, 1 September 1993 (1993-09-01), pages 3976 - 3985, XP001160867, ISSN: 0008-5472 *
LAZEBNIK Y A ET AL: "Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.", NATURE. 22 SEP 1994, vol. 371, no. 6495, 22 September 1994 (1994-09-22), pages 346 - 347, XP001183582, ISSN: 0028-0836 *
NICHOLSON D W ET AL: "IDENTIFICATION AND INHIBITION OF THE ICE/CED-3 PROTEASE NECESSARY FOR MAMMALIAN APOPTOSIS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 376, no. 6535, 6 July 1995 (1995-07-06), pages 37 - 43, XP000574812, ISSN: 0028-0836 *
See also references of WO9633268A1 *
TEWARI M ET AL: "YAMACPP32BETA, A MAMMALIAN HOMOLOG OF CED-3, IS A CRMA-INHIBITABLE PROTEASE THAT CLEAVES THE DEATH SUBSTRATE POLY(ADP-RIBOSE)POLYMERASE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 81, 2 June 1995 (1995-06-02), pages 801 - 809, XP002013933, ISSN: 0092-8674 *
THORNBERRY N A ET AL: "A NOVEL HETERODIMERIC CYSTEINE PROTEASE IS REQUIRED FOR INTERLEUKIN-1BETA PROCESSING IN MONOCYTES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 356, 30 April 1992 (1992-04-30), pages 768 - 774, XP000986114, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO1996033268A1 (fr) 1996-10-24
CA2218679A1 (fr) 1996-10-24
JPH11504209A (ja) 1999-04-20
EP0822983A1 (fr) 1998-02-11

Similar Documents

Publication Publication Date Title
DE69513693D1 (en) Positions-servo-system
DE59607964D1 (en) Oxymethoxy-3-aryl-pyron-derivate
DE69608292D1 (en) Audio-synthesizer
DE59607241D1 (en) Endotracheal-tubus
DE69606427D1 (en) Hydroformylierungsverfahren
DE69611623D1 (en) Polyurethanelastomere
EP0822983A4 (fr) Apopaine
DE69610843D1 (en) Hydroformylierungsverfahren
DE69516545D1 (en) Polyacetalharzzusammensetzung
DE59610991D1 (en) Cyclopeptidderivate
DE59608164D1 (en) Cyclohexenonoximether-metallsalze
DE59605001D1 (en) Luftreinigungsgerät
DE59602888D1 (en) Breitstreckaggregat
DE59602283D1 (en) Inchbremseinrichtung
DE59602030D1 (en) Zellige polyurethan-elastomere
DE69611833D1 (en) Carbonylierungsreaktionen
DE59505396D1 (en) Handhobelmaschine
DE69612563D1 (en) Hydroformylierungsverfahren
DE69610077D1 (en) Sesquiterpenverbindungen
AP9600802A0 (en) Libricant
DE59600830D1 (en) Breitstrahldüse
DE59604506D1 (en) Rückkühlsystem
DE59604913D1 (en) Carbonylverbindungen
DE59609059D1 (en) Conventional-direct-glazing
AU1105P (en) DALESE Metrosideros excelsus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK FROSST CANADA & CO.

Owner name: MERCK & CO., INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20041102

17Q First examination report despatched

Effective date: 20041215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050626